Prophylactic use of hematopoietic colony stimulating factors (g-csf/gm/csf) / (Record no. 4727)

000 -LEADER
fixed length control field 02324nam a22002177a 4500
003 - CONTROL NUMBER IDENTIFIER
control field DOH
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20210519102349.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 210519b ||||| |||| 00| 0 eng d
245 00 - TITLE STATEMENT
Title Prophylactic use of hematopoietic colony stimulating factors (g-csf/gm/csf) /
Statement of responsibility, etc. Degracias B. Custodio [and two others]
520 3# - SUMMARY, ETC.
Summary, etc. Although multi-agent chemotherapy regimens have increased the cure rate of most malignancies, this success has frequently been accompanied by an increased risk of potentially life-threatening hematologic toxicities and infectious complications. The use of hematologic growth factors such as the Colony Stimulating Factors (G-CSF / GM-CSF) reduces the incidence of myelosuppression following intravenous chemotherapy. The purpose of this study is to assess whether (G-CSF / GM-CSF administered concurrently with chemotherapeutic agents reduce the incidence of myelotoxicity. This would decrease the incidence of infectious complications and the use of antibiotics, length of hospital stay, the over all cost, and delay in the administration of succeeding chemotherapy. This is a one year prospective clinical trial and cost-effectivity study designed to include cancer patients admitted at the Makati Medical Center for intravenous chemotherapy. There were 180 patients eligible for the study as described by the criteria. The results showed that 100% of the control group had a decrease in the level of myelocytes, 75% of the G-CSF group had an increase in the level of myelocytes and 85% of the GM-CSF group had an increase in the level of myelocytes and platelet count after intravenous chemotherapy. The conclusion of the study is that the prophylactic use of Colony Stimulating Factors is needed in subsequent cycles of chemotherapy in patients with history of myelosuppression during their previous chemotherapy, thereby reducing the over-all cost and length of hospital stay.
580 ## - LINKING ENTRY COMPLEXITY NOTE
Linking entry complexity note <br/><br/>Makati Medical Center Proceedings, 1999 (13) pages 11-19
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Colony-Stimulating Factors
General subdivision therapeutic use
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antineoplastic Agents
General subdivision therapeutic use
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Hospitalization
General subdivision economics
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Prospective Studies
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Custodio, Degracias B.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Esmaquel, Pelagio L.
Titles and other words associated with a name Jr.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Sarmiento, Josierina Y.
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
999 ## -
-- 4727
-- 4727
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Home library Current library Shelving location Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
    National Library of Medicine     DOH Central Library DOH Central Library Electronic Resource Section 05/19/2021   J000650 D0001J000650 05/19/2021 05/19/2021 Journal Article